Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma
International Journal of Urology · 2023
DOI: 10.1111/iju.15198 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2023. Verfasst von Nami Tomiyama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Nitto Foundation.
Abstract (Originalsprache)
Objective
To identify biomarkers associated with the effectiveness of ipilimumab plus nivolumab against advanced metastatic renal cell carcinoma.
Methods
We retrospectively analyzed the data of 75 patients treated with ipilimumab plus nivolumab at seven hospitals between August 2018 and April 2021. Prognostic biomarkers were assessed prior to initiating treatment with ipilimumab plus nivolumab. Median overall survival and progression‐free survival were examined using the Kaplan–Meier method. Univariate and multivariate analyses were performed to identify predictors of disease progression. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors most important for predicting disease progression were determined using classification and regression tree analysis.
Results
Median overall survival and progression‐free survival were longer in the intermediate IMDC risk group than in the poor IMDC risk group (overall: not reached vs. 18.3 months; progression‐free: not reached vs. 13.5 months). The multivariate analysis identified poor IMDC risk as a risk factor for disease progression (hazard ratio 2.61, 95% confidence interval: 1.05–6.51). Based on the results of the classification and regression tree analysis, the cohort was divided into non‐anemia, anemia + neutro‐Low, and anemia + neutro‐High groups. Median overall survival and progression‐free survival were longer in the non‐anemia and anemia + neutro‐Low groups than in the anemia + neutro‐High group (overall: not reached vs. 29.3 months vs. 4.3 months: progression‐free: not reached vs. 29.0 months vs. 3.9 months).
Conclusion
Hemoglobin and neutrophil levels may represent crucial biomarkers for predicting the effectiveness of ipilimumab plus nivolumab therapy in patients with renal cell carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Urology, Toyota Kosei Hospital, Toyota, Aichi, Japan.
- Department of Urology, Nagoya East Medical Center, Nagoya, Aichi, Japan.
- Department of Urology, Anjo Kosei Hospital, Anjo, Aichi, Japan.
- Department of Urology, Nagoya Tokushukai General Hospital, Kasugai, Aichi, Japan.
ORCID-Profile: Nami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Atsushi Okada, Noriyasu Kawai, Yoko Furukawa-Hibi, Takahiro Yasui
Förderung
- Nitto Foundation
Zitieren
APA
Tomiyama, N., Tasaki, Y., Hamamoto, S., Sugiyama, Y., Naiki, T., Etani, T., Taguchi, K., Matsuyama, N., Sue, Y., Mimura, Y., Odagiri, K., Noda, Y., Aoki, M., Moritoki, Y., Nozaki, S., Kurokawa, S., Okada, A., Kawai, N., Furukawa-Hibi, Y., & Yasui, T. (2023). Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.15198
Vancouver
Tomiyama N, Tasaki Y, Hamamoto S, Sugiyama Y, Naiki T, Etani T, et al. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. International Journal of Urology. 2023. doi:10.1111/iju.15198
BibTeX
@article{Tomiyama2023,
author = {Tomiyama, Nami and Tasaki, Yoshihiko and Hamamoto, Shuzo and Sugiyama, Yosuke and Naiki, Taku and Etani, Toshiki and Taguchi, Kazumi and Matsuyama, Nayuka and Sue, Yasuhito and Mimura, Yoshihisa and Odagiri, Kunihiro and Noda, Yusuke and Aoki, Maria and Moritoki, Yoshinobu and Nozaki, Satoshi and Kurokawa, Satoshi and Okada, Atsushi and Kawai, Noriyasu and Furukawa-Hibi, Yoko and Yasui, Takahiro},
title = {Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma},
journal = {International Journal of Urology},
year = {2023},
doi = {10.1111/iju.15198}
}
EUVIMED